FDA Authorizes OraSure's Next-Gen Ebola Test Amid Deadly Bundibugyo Outbreak
OSUR sits 89% above its 52-week low of $2.08.
Summary
OraSure received FDA Emergency Use Authorization for its second-generation OraQuick Ebola 2.0 Rapid Antigen Test. The test detects all four Ebola viruses, including Bundibugyo, which is driving a current outbreak in Central Africa with hundreds of deaths and no approved vaccine. This follows the company's recent FDA clearance for its Colli-Pee urine collection kit, adding another regulatory win. The EUA positions OraSure to supply a critical diagnostic tool during a WHO-declared global health emergency, with the company ramping production to meet potential demand. The test's improved sensitivity and automated manufacturing could strengthen OraSure's infectious disease portfolio and open near-term revenue opportunities.
At the time of this announcement, OSUR was trading at $3.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $261.6M. The 52-week trading range was $2.08 to $4.58. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.